<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8055">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861146</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAA-Cooney-AA011197</org_study_id>
    <secondary_id>R01AA011197</secondary_id>
    <secondary_id>NIH Grant R01AA011197</secondary_id>
    <nct_id>NCT00861146</nct_id>
  </id_info>
  <brief_title>Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk</brief_title>
  <official_title>Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The majority of individuals with alcohol problems remain current smokers, and the negative
      health consequences of smoking among these individuals are substantial. This study will
      investigate the impact of smoking cessation interventions initiated during intensive alcohol
      treatment on processes reflecting risk of alcohol relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      Most alcohol and drug treatment programs do not systematically address cigarette smoking
      during treatment. One obstacle is a concern that smoking cessation early in recovery might
      increase risk of alcohol relapse. This study followed patients enrolled in intensive
      outpatient alcohol treatment to compare the effects of a Concurrent Smoking Cessation (CSC)
      intervention to a Deferred Smoking Cessation (DSC) control group on process measures
      reflecting risk of alcohol relapse.

      Research Design:

      Participants were enrolled in intensive outpatient alcohol treatment and then randomized to
      CSC or DSC groups in a 2:1 ratio. The CSC group received smoking treatment concurrent with
      intensive alcohol treatment and the DSC group received smoking treatment three months after
      alcohol treatment. The smoking treatment protocol included behavioral counseling,
      contingency management with voucher rewards for verified smoking abstinence, and prescribed
      nicotine patch and gum. During a three-month period after the CSC target smoking quit date,
      both groups of subjects were asked to participate in a prospective daily monitoring
      procedure, calling into an Interactive Voice Response system once a day to complete
      self-report assessments of relapse risk factors. By comparing participants in the CSC group
      composed of many participants who have stopped smoking with the DSC group who are expected
      to continue smoking during this daily monitoring period, we will determine the impact of
      smoking cessation on alcohol relapse risk factors.

      Methodology:

      This study was conducted in the substance abuse day treatment programs located at Newington
      and West Haven campuses of VA Connecticut Healthcare System. These are three-week treatment
      programs meeting Monday-Friday for 4-5 hrs/day. Participants were recruited either before or
      soon after day program admission. Participants 151 individuals that are 18 years of age or
      older, meet Diagnostic and Statistical Manual-IV (DSM-IV) criteria for current alcohol abuse
      or dependence, report currently smoking 1 or more cigarettes per day, and are screened for
      medical contraindications for nicotine patch and gum use. Dependent variables are process
      assessments reflecting alcohol relapse risk obtained using daily Interactive Voice Response
      (IVR) technology. These relapse risk processes include alcohol craving, negative affect,
      alcohol abstinence self efficacy, alcohol outcome expectancies, motivation for alcohol
      abstinence, and self-control demands. Given the mixed results from previous clinical trials,
      we conducted bidirectional tests of the hypothesis that smoking cessation has an impact on
      alcohol relapse risk factors, examining whether smoking cessation leads to increased or
      decreased alcohol relapse risk.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Smoking Abstinence</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>7-day point prevalence smoking abstinence verified by breath carbon monoxide missing coded as smoking</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Smoking Abstinence</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>7-day point prevalence smoking abstinence verified by breath carbon monoxide missing coded as smoking</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Days Heavy Drinking</measure>
    <time_frame>follow-up weeks 9-12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Heavy drinking days were defined as days with &gt; 6 standard drinks per day for men and &gt; 4 standard drinks per day for women. This measure examined the proportion of days heavy drinking across 28 days in follow-up weeks 9-12.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Tobacco Use Cessation</condition>
  <condition>Alcohol-related Disorders</condition>
  <arm_group>
    <arm_group_label>1 concurrent smoking cessation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>smoking cessation delivered concurrent with intensive alcohol treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 deferred smoking cessation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>smoking cessation delivered 12 weeks after intensive alcohol treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>behavioral counseling plus contingency management</intervention_name>
    <description>Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
    <arm_group_label>1 concurrent smoking cessation</arm_group_label>
    <arm_group_label>2 deferred smoking cessation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV criteria for alcohol abuse or dependence

          -  Age 18 or older

          -  English speaking

          -  Smoking 1 or more cigarettes/day

          -  Male or female veterans eligible for VA healthcare

          -  Female nonveterans also eligible

        Exclusion Criteria:

          -  Allergy or hypersensitivity to nicotine or adhesives used in nicotine patch

          -  Weigh less than 100 lbs

          -  Lack of interest in stopping smoking

          -  Pregnant or lactating females or females not practicing acceptable form of
             contraception
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ned L Cooney, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>Newington</city>
        <state>Connecticut</state>
        <zip>06111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>March 11, 2009</firstreceived_date>
  <firstreceived_results_date>January 15, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Ned Cooney</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>nicotine dependence</keyword>
  <keyword>tobacco dependence</keyword>
  <keyword>smoking cessation</keyword>
  <keyword>alcoholism</keyword>
  <keyword>self-efficacy</keyword>
  <keyword>relapse</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcohol-Related Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment May 2009 to October 2012.
Excluded (n=1448):
Does not smoke, does not drink (n=678) Declined to participate (n=320) Medical problems (n=297) Otherwise ineligible (n=112) Male non-vet (n=41)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Concurrent Smoking Cessation</title>
          <description>smoking cessation delivered concurrent with intensive alcohol treatment
behavioral counseling plus contingency management: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
        </group>
        <group group_id="P2">
          <title>2 Deferred Smoking Cessation</title>
          <description>smoking cessation delivered 12 weeks after intensive alcohol treatment
behavioral counseling plus contingency management: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 2 Assessment</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 13 Assessment</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Concurrent Smoking Cessation</title>
          <description>smoking cessation delivered concurrent with intensive alcohol treatment
behavioral counseling plus contingency management: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
        </group>
        <group group_id="B2">
          <title>2 Deferred Smoking Cessation</title>
          <description>smoking cessation delivered 12 weeks after intensive alcohol treatment
behavioral counseling plus contingency management: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
                <measurement group_id="B2" value="46"/>
                <measurement group_id="B3" value="151"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="49.5" spread="9.07"/>
                <measurement group_id="B2" value="48.1" spread="8.68"/>
                <measurement group_id="B3" value="49.1" spread="8.95"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="91"/>
                <measurement group_id="B2" value="39"/>
                <measurement group_id="B3" value="130"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="63"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="82"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
                <measurement group_id="B2" value="46"/>
                <measurement group_id="B3" value="151"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Cigarettes smoked/day</title>
          <units>cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16.0" spread="8.0"/>
                <measurement group_id="B2" value="16.8" spread="10.0"/>
                <measurement group_id="B3" value="16.2" spread="8.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Proportion days heavy drinking</title>
          <description>Heavy drinking days were defined as days with &gt; 6 standard drinks per day for men and &gt; 4 standard drinks per day for women. The baseline measure examined the proportion of heavy drinking days in the 90 days prior to the last day of reported drinking prior to study enrollment.</description>
          <units>proportion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value=".58" spread=".33"/>
                <measurement group_id="B2" value=".52" spread=".38"/>
                <measurement group_id="B3" value=".56" spread=".35"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Smoking Abstinence</title>
        <description>7-day point prevalence smoking abstinence verified by breath carbon monoxide missing coded as smoking</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>1 Concurrent Smoking Cessation</title>
            <description>smoking cessation delivered concurrent with intensive alcohol treatment
behavioral counseling plus contingency management: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
          </group>
          <group group_id="O2">
            <title>2 Deferred Smoking Cessation</title>
            <description>smoking cessation delivered 12 weeks after intensive alcohol treatment
behavioral counseling plus contingency management: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Smoking Abstinence</title>
            <description>7-day point prevalence smoking abstinence verified by breath carbon monoxide missing coded as smoking</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;.01</p_value>
            <method>Chi-squared</method>
            <method_desc>df = 1</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Days Heavy Drinking</title>
        <description>Heavy drinking days were defined as days with &gt; 6 standard drinks per day for men and &gt; 4 standard drinks per day for women. This measure examined the proportion of days heavy drinking across 28 days in follow-up weeks 9-12.</description>
        <time_frame>follow-up weeks 9-12</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>1 Concurrent Smoking Cessation</title>
            <description>smoking cessation delivered concurrent with intensive alcohol treatment
behavioral counseling plus contingency management: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
          </group>
          <group group_id="O2">
            <title>2 Deferred Smoking Cessation</title>
            <description>smoking cessation delivered 12 weeks after intensive alcohol treatment
behavioral counseling plus contingency management: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="85"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Days Heavy Drinking</title>
            <description>Heavy drinking days were defined as days with &gt; 6 standard drinks per day for men and &gt; 4 standard drinks per day for women. This measure examined the proportion of days heavy drinking across 28 days in follow-up weeks 9-12.</description>
            <units>proportion of days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value=".0332" spread=".1130"/>
                  <measurement group_id="O2" value=".0132" spread=".0375"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Drinking outcomes assessed using the timeline follow-back were evaluated with mixed model regression analyses using maximum likelihood estimation. Time was measured in three monthly periods and treated as a repeated factor (due to the fixed time period between estimates).</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&gt; .15</p_value>
            <method>mixed model regression analyses</method>
            <param_type>mixed model regression analyses (F)</param_type>
            <param_value>2.04</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Smoking Abstinence</title>
        <description>7-day point prevalence smoking abstinence verified by breath carbon monoxide missing coded as smoking</description>
        <time_frame>2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>1 Concurrent Smoking Cessation</title>
            <description>smoking cessation delivered concurrent with intensive alcohol treatment
behavioral counseling plus contingency management: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
          </group>
          <group group_id="O2">
            <title>2 Deferred Smoking Cessation</title>
            <description>smoking cessation delivered 12 weeks after intensive alcohol treatment
behavioral counseling plus contingency management: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Smoking Abstinence</title>
            <description>7-day point prevalence smoking abstinence verified by breath carbon monoxide missing coded as smoking</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;.001</p_value>
            <method>Chi-squared</method>
            <method_desc>df=1</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 Concurrent Smoking Cessation</title>
          <description>smoking cessation delivered concurrent with intensive alcohol treatment
behavioral counseling plus contingency management: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
        </group>
        <group group_id="E2">
          <title>2 Deferred Smoking Cessation</title>
          <description>smoking cessation delivered 12 weeks after intensive alcohol treatment
behavioral counseling plus contingency management: Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization gastrointestinal</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization stroke</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization psychiatric</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hospitalization alcohol</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>heartburn or indigestion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>vivid dreams</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="105"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>coughing</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>hiccups</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>itching or irritation</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="105"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ned L. Cooney, PhD</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>860-594-6339</phone>
      <email>ned.cooney@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
